Impact of Sarcopenia and Osteopenia on Prognosis in Metastatic Biliary Tract Cancer: A Single Center Experience.

IF 2 4区医学 Q3 NUTRITION & DIETETICS

Nutrition and Cancer-An International Journal Pub Date : 2025-01-01 Epub Date: 2025-05-06 DOI:10.1080/01635581.2025.2496371

Nadiye Sever, Emil Yunusov, Elçin İrem Çağlar, Abdussamet Çelebi, Nargiz Majidova, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Güren, Burak Paçacı, Mustafa Alperen Tunç, Selver Işık, Rukiye Arıkan, İbrahim Vedat Bayoğlu, Murat Sarı, Canan Cimşit, Osman Köstek

{"title":"Impact of Sarcopenia and Osteopenia on Prognosis in Metastatic Biliary Tract Cancer: A Single Center Experience.","authors":"Nadiye Sever, Emil Yunusov, Elçin İrem Çağlar, Abdussamet Çelebi, Nargiz Majidova, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Güren, Burak Paçacı, Mustafa Alperen Tunç, Selver Işık, Rukiye Arıkan, İbrahim Vedat Bayoğlu, Murat Sarı, Canan Cimşit, Osman Köstek","doi":"10.1080/01635581.2025.2496371","DOIUrl":null,"url":null,"abstract":"Sarcopenia, defined as skeletal muscle loss, has been known as a poor prognosis factor in various malignant diseases. We aimed to investigate the effect of sarcopenia on prognosis in patients with metastatic biliary tract cancer (mBTC) who received chemotherapy. We retrospectively collected clinic data of 70 patients with mBTC. Computed tomography scans were used to determine the skeletal muscle index at the third lumbar vertebra level for sarcopenia. Osteopenia was defined by averaging the radiodensity of consecutive five lumbar vertebrae in non-contrast CT scan images. Overall survival (OS) and progression free survival (PFS) were analyzed according to sarcopenia and osteopenia. Sarcopenia was present in 39 (55.7%) patients. Osteopenia was present 36 (51.4%) patients. Median PFS was 3.4 (2.7-4.1) and 6.5 (5.1-8.0) months in the sarcopenia and non- sarcopenia groups. Median OS was 4.1 (3.3-4.8) and 13.2 (9.9-16.4) months in the sarcopenia and non- sarcopenia groups. On multivariate analysis, the presence of sarcopenia (HR: 3.22, p = 0.001) and male sex (HR: 1.91, p = 0.02) were an independent predictor of poor OS. Osteopenia was not significantly associated with PFS and OS. Sarcopenia was associated with poor survival for metastatic BTC. Our aim was to raise awareness by emphasizing modifiable factors.","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"610-618"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition and Cancer-An International Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/01635581.2025.2496371","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Sarcopenia, defined as skeletal muscle loss, has been known as a poor prognosis factor in various malignant diseases. We aimed to investigate the effect of sarcopenia on prognosis in patients with metastatic biliary tract cancer (mBTC) who received chemotherapy. We retrospectively collected clinic data of 70 patients with mBTC. Computed tomography scans were used to determine the skeletal muscle index at the third lumbar vertebra level for sarcopenia. Osteopenia was defined by averaging the radiodensity of consecutive five lumbar vertebrae in non-contrast CT scan images. Overall survival (OS) and progression free survival (PFS) were analyzed according to sarcopenia and osteopenia. Sarcopenia was present in 39 (55.7%) patients. Osteopenia was present 36 (51.4%) patients. Median PFS was 3.4 (2.7-4.1) and 6.5 (5.1-8.0) months in the sarcopenia and non- sarcopenia groups. Median OS was 4.1 (3.3-4.8) and 13.2 (9.9-16.4) months in the sarcopenia and non- sarcopenia groups. On multivariate analysis, the presence of sarcopenia (HR: 3.22, p = 0.001) and male sex (HR: 1.91, p = 0.02) were an independent predictor of poor OS. Osteopenia was not significantly associated with PFS and OS. Sarcopenia was associated with poor survival for metastatic BTC. Our aim was to raise awareness by emphasizing modifiable factors.

查看原文本刊更多论文

骨骼肌减少和骨质减少对转移性胆道癌预后的影响：单一中心经验。

骨骼肌减少症，定义为骨骼肌损失，已被认为是各种恶性疾病的预后不良因素。我们旨在探讨肌肉减少症对接受化疗的转移性胆道癌（mBTC）患者预后的影响。我们回顾性收集了70例mBTC患者的临床资料。计算机断层扫描用于确定肌肉减少症患者第三腰椎水平的骨骼肌指数。通过在非对比CT扫描图像中平均连续五个腰椎的放射密度来定义骨质减少。根据骨骼肌减少症和骨质减少症分析总生存期（OS）和无进展生存期（PFS）。39例（55.7%）患者出现肌肉减少症。骨质减少36例（51.4%）。肌少症组和非肌少症组的中位PFS分别为3.4（2.7-4.1）和6.5（5.1-8.0）个月。肌少症组和非肌少症组的中位生存期分别为4.1（3.3-4.8）和13.2（9.9-16.4）个月。在多变量分析中，肌肉减少症（HR: 3.22, p = 0.001）和男性（HR: 1.91, p = 0.02）是不良OS的独立预测因子。骨质减少与PFS和OS无显著相关性。肌少症与转移性BTC的低生存率相关。我们的目的是通过强调可改变的因素来提高人们的认识。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutrition and Cancer-An International Journal 医学-营养学

CiteScore

5.80

自引率

3.40%

发文量

172

审稿时长

3 months

期刊介绍： This timely publication reports and reviews current findings on the effects of nutrition on the etiology, therapy, and prevention of cancer. Etiological issues include clinical and experimental research in nutrition, carcinogenesis, epidemiology, biochemistry, and molecular biology. Coverage of therapy focuses on research in clinical nutrition and oncology, dietetics, and bioengineering. Prevention approaches include public health recommendations, preventative medicine, behavior modification, education, functional foods, and agricultural and food production policies.